Posted by Michael Wonder on 18 Dec 2021
Tezspire (tezepelumab) approved in the US for severe asthma
17 December 2021 - Only biologic for severe asthma approved with no phenotype or biomarker limitations
AstraZeneca and Amgen’s Tezspire (tezepelumab-ekko) has been approved in the US for the add-on maintenance treatment of adult and paediatric patients aged 12 years and older with severe asthma.
